Prelude Therapeutics Stock Probability of Future Stock Price Finishing Under 1.27
| PRLD Stock | USD 1.34 0.06 4.29% |
Prelude |
Prelude Therapeutics Target Price Odds to finish below 1.27
The tendency of Prelude Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to drop to $ 1.27 or more in 90 days |
| 1.34 | 90 days | 1.27 | about 39.83 |
Based on a normal probability distribution, the odds of Prelude Therapeutics to drop to $ 1.27 or more in 90 days from now is about 39.83 (This Prelude Therapeutics probability density function shows the probability of Prelude Stock to fall within a particular range of prices over 90 days) . Probability of Prelude Therapeutics price to stay between $ 1.27 and its current price of $1.34 at the end of the 90-day period is about 6.39 .
Given the investment horizon of 90 days Prelude Therapeutics has a beta of 0.8 indicating as returns on the market go up, Prelude Therapeutics average returns are expected to increase less than the benchmark. However, during the bear market, the loss on holding Prelude Therapeutics will be expected to be much smaller as well. Additionally Prelude Therapeutics has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the Dow Jones Industrial. Prelude Therapeutics Price Density |
| Price |
Predictive Modules for Prelude Therapeutics
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Prelude Therapeutics. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Prelude Therapeutics Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Prelude Therapeutics is not an exception. The market had few large corrections towards the Prelude Therapeutics' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Prelude Therapeutics, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Prelude Therapeutics within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -0.44 | |
β | Beta against Dow Jones | 0.80 | |
σ | Overall volatility | 0.43 | |
Ir | Information ratio | -0.06 |
Prelude Therapeutics Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Prelude Therapeutics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Prelude Therapeutics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Prelude Therapeutics generated a negative expected return over the last 90 days | |
| Prelude Therapeutics has high historical volatility and very poor performance | |
| Prelude Therapeutics may become a speculative penny stock | |
| Prelude Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (121.83 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Prelude Therapeutics currently holds about 246.3 M in cash with (107.06 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.19, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Prelude Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Over 85.0% of the company shares are owned by institutional investors | |
| Latest headline from gurufocus.com: Insider Buying Andrew Combs Acquires 63,075 Shares of Prelude Therapeutics Inc |
Prelude Therapeutics Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Prelude Stock often depends not only on the future outlook of the current and potential Prelude Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Prelude Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 60.4 M | |
| Cash And Short Term Investments | 232.9 M |
Prelude Therapeutics Technical Analysis
Prelude Therapeutics' future price can be derived by breaking down and analyzing its technical indicators over time. Prelude Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Prelude Therapeutics. In general, you should focus on analyzing Prelude Stock price patterns and their correlations with different microeconomic environments and drivers.
Prelude Therapeutics Predictive Forecast Models
Prelude Therapeutics' time-series forecasting models is one of many Prelude Therapeutics' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Prelude Therapeutics' historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.
Things to note about Prelude Therapeutics
Checking the ongoing alerts about Prelude Therapeutics for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Prelude Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
| Prelude Therapeutics generated a negative expected return over the last 90 days | |
| Prelude Therapeutics has high historical volatility and very poor performance | |
| Prelude Therapeutics may become a speculative penny stock | |
| Prelude Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (121.83 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Prelude Therapeutics currently holds about 246.3 M in cash with (107.06 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.19, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Prelude Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Over 85.0% of the company shares are owned by institutional investors | |
| Latest headline from gurufocus.com: Insider Buying Andrew Combs Acquires 63,075 Shares of Prelude Therapeutics Inc |
Check out Prelude Therapeutics Backtesting, Prelude Therapeutics Valuation, Prelude Therapeutics Correlation, Prelude Therapeutics Hype Analysis, Prelude Therapeutics Volatility, Prelude Therapeutics History as well as Prelude Therapeutics Performance. For information on how to trade Prelude Stock refer to our How to Trade Prelude Stock guide.You can also try the Portfolio Center module to all portfolio management and optimization tools to improve performance of your portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Prelude Therapeutics. If investors know Prelude will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Prelude Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.77) | Revenue Per Share 0.04 | Return On Assets (0.39) | Return On Equity (0.67) |
The market value of Prelude Therapeutics is measured differently than its book value, which is the value of Prelude that is recorded on the company's balance sheet. Investors also form their own opinion of Prelude Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Prelude Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Prelude Therapeutics' market value can be influenced by many factors that don't directly affect Prelude Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Prelude Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Prelude Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Prelude Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.